Open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects

Borimas Hanboonkunupakarn, Elizabeth A Ashley, Podjanee Jittamala, Joel Tarning, Sasithon Pukrittayakamee, Warunee Hanpithakpong, Palang Chotsiri, Thanaporn Wattanakul, Salwaluk Panapipat, Sue J Lee, Nicholas P J Day, Nicholas J White, Borimas Hanboonkunupakarn, Elizabeth A Ashley, Podjanee Jittamala, Joel Tarning, Sasithon Pukrittayakamee, Warunee Hanpithakpong, Palang Chotsiri, Thanaporn Wattanakul, Salwaluk Panapipat, Sue J Lee, Nicholas P J Day, Nicholas J White

Abstract

Dihydroartemisinin-piperaquine is an artemisinin-based combination treatment (ACT) recommended by the WHO for uncomplicated Plasmodium falciparum malaria, and it is being used increasingly for resistant vivax malaria where combination with primaquine is required for radical cure. The WHO recently reinforced its recommendations to add a single dose of primaquine to ACTs to reduce P. falciparum transmission in low-transmission settings. The pharmacokinetics of primaquine and dihydroartemisinin-piperaquine were evaluated in 16 healthy Thai adult volunteers in a randomized crossover study. Volunteers were randomized to two groups of three sequential hospital admissions to receive 30 mg (base) primaquine, 3 tablets of dihydroartemisinin-piperaquine (120/960 mg), and the drugs together at the same doses. Blood sampling was performed over 3 days following primaquine and 36 days following dihydroartemisinin-piperaquine dosing. Pharmacokinetic assessment was done with a noncompartmental approach. The drugs were well tolerated. There were no statistically significant differences in dihydroartemisinin and piperaquine pharmacokinetics with or without primaquine. Dihydroartemisinin-piperaquine coadministration significantly increased plasma primaquine levels; geometric mean ratios (90% confidence interval [CI]) of primaquine combined versus primaquine alone for maximum concentration (Cmax), area under the concentration-time curve from 0 h to the end of the study (AUC0-last), and area under the concentration-time curve from 0 h to infinity (AUC0-∞) were 148% (117 to 187%), 129% (103 to 163%), and 128% (102 to 161%), respectively. This interaction is similar to that described recently with chloroquine and may result in an enhanced radical curative effect. (This study has been registered at ClinicalTrials.gov under registration no. NCT01525511.).

Copyright © 2014 Hanboonkunupakarn et al.

Figures

FIG 1
FIG 1
Mean venous plasma concentration-time curves of primaquine (A), carboxyprimaquine (B), dihydroartemisinin (C), and piperaquine (D) in healthy volunteers. Error bars indicate SDs.
FIG 2
FIG 2
Forest plots of the geometric mean ratios (90% CI) of the drug administered with and without interacting drug for the logarithmically transformed Cmax, AUC0–last, and AUC0–∞. Vertical dashed lines represent the U.S. FDA criteria of 80 to 125% for assuming bioequivalence.

References

    1. World Health Organization. 2012. Updated WHO policy recommendation (October 2012): single dose primaquine as a gametocytocide in Plasmodium falciparum malaria. World Health Organization, Geneva, Switzerland.
    1. World Health Organization. 2010. Guidelines for the treatment of malaria, 2nd ed. World Health Organization, Geneva, Switzerland.
    1. White NJ, Qiao LG, Qi G, Luzzatto L. 2012. Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malar. J. 11:418. 10.1186/1475-2875-11-418.
    1. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN. 2010. Artemisinin combination therapy for vivax malaria? Lancet Infect. Dis. 10:405–416. 10.1016/S1473-3099(10)70079-7.
    1. Leang R, Barrette A, Bouth DM, Menard D, Abdur R, Duong S, Ringwald P. 2013. Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob. Agents Chemother. 57:818–826. 10.1128/AAC.00686-12.
    1. World Health Organization. December 2012. Country antimalarial drug policies: by region. World Health Organization, Geneva, Switzerland: .
    1. World Health Organization. December 2012. Country antimalarial drug policies: by region. World Health Organization, Geneva, Switzerland: .
    1. Edwards G, McGrath CS, Ward SA, Supanaranond W, Pukrittayakamee S, Davis TM, White NJ. 1993. Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. Br. J. Clin. Pharmacol. 35:193–198. 10.1111/j.1365-2125.1993.tb05685.x.
    1. Navaratnam V, Ramanathan S, Wahab MS, Siew Hua G, Mansor SM, Kiechel JR, Vaillant M, Taylor WR, Olliaro P. 2009. Tolerability and pharmacokinetics of nonfixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteers. Eur. J. Clin. Pharmacol. 65:809–821. 10.1007/s00228-009-0656-1.
    1. Chinh NT, Quang NN, Thanh NX, Dai B, Geue JP, Addison RS, Travers T, Edstein MD. 2009. Pharmacokinetics and bioequivalence evaluation of two fixed-dose tablet formulations of dihydroartemisinin and piperaquine in Vietnamese subjects. Antimicrob. Agents Chemother. 53:828–831. 10.1128/AAC.00927-08.
    1. Hanpithakpong W, Kamanikom B, Dondorp AM, Singhasivanon P, White NJ, Day NP, Lindegardh N. 2008. A liquid chromatographic-tandem mass spectrometric method for determination of artesunate and its metabolite dihydroartemisinin in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 876:61–68. 10.1016/j.jchromb.2008.10.018.
    1. Lindegardh N, Annerberg A, White NJ, Day NP. 2008. Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of piperaquine in plasma stable isotope labeled internal standard does not always compensate for matrix effects. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 862:227–236. 10.1016/j.jchromb.2007.12.011.
    1. Pukrittayakamee S, Tarning J, Jittamala P, Charunwatthana P, Lawpoolsri S, Lee SJ, Hanpithakpong W, Hanboonkunupakarn B, Day NPJ, Ashley EA, White NJ. 2014. Pharmacokinetic interactions between primaquine and chloroquine. Antimicrob. Agents Chemother. 58:3354–3359. 10.1128/AAC.02794-13.
    1. US Food and Drug Administration. 2003. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products. U.S. Food and Drug Administration, Rockville, MD.
    1. Sim IK, Davis TM, Ilett KF. 2005. Effects of a high-fat meal on the relative oral bioavailability of piperaquine. Antimicrob. Agents Chemother. 49:2407–2411. 10.1128/AAC.49.6.2407-2411.2005.
    1. Nguyen TC, Nguyen NQ, Nguyen XT, Bui D, Travers T, Edstein MD. 2008. Pharmacokinetics of the antimalarial drug piperaquine in healthy Vietnamese subjects. Am. J. Trop. Med. Hyg. 79:620–623.
    1. Annerberg A, Lwin KM, Lindegardh N, Khrutsawadchai S, Ashley E, Day NP, Singhasivanon P, Tarning J, White NJ, Nosten F. 2011. A small amount of fat does not affect piperaquine exposure in patients with malaria. Antimicrob. Agents Chemother. 55:3971–3976. 10.1128/AAC.00279-11.
    1. Tarning J, Lindegardh N, Lwin KM, Annerberg A, Kiricharoen L, Ashley E, White NJ, Nosten F, Day NP. 2014. Population pharmacokinetic assessment of the effect of food on piperaquine bioavailability in patients with uncomplicated malaria. Antimicrob. Agents Chemother. 58:2052–2058. 10.1128/AAC.02318-13.
    1. Elmes NJ, Bennett SM, Abdalla H, Carthew TL, Edstein MD. 2006. Lack of sex effect on the pharmacokinetics of primaquine. Am. J. Trop. Med. Hyg. 74:951–952.
    1. Binh VQ, Chinh NT, Thanh NX, Cuong BT, Quang NN, Dai B, Travers T, Edstein MD. 2009. Sex affects the steady-state pharmacokinetics of primaquine but not doxycycline in healthy subjects. Am. J. Trop. Med. Hyg. 81:747–753. 10.4269/ajtmh.2009.09-0214.
    1. Chen G, Geiling EM. 1947. The acute joint toxicity of atabrine, quinine, hydroxyethylapocupreine, pamaquine and pentaquine. J. Pharmacol. Exp. Ther. 91:133–139.
    1. Berliner RW, Earle DP, Taggart JV, Welch WJ, Zubrod CG, Knowlton P, Atchley JA, Shannon JA. 1948. Studies on the chemotherapy of the human malarias. VII. The antimalarial activity of pamaquine. J. Clin. Invest. 27:108–113.
    1. Grover A, Benet LZ. 2009. Effects of drug transporters on volume of distribution. AAPS J. 11:250–261. 10.1208/s12248-009-9102-7.
    1. Mihaly GW, Ward SA, Edwards G, Nicholl DD, Orme ML, Breckenridge AM. 1985. Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. Br. J. Clin. Pharmacol. 19:745–750.
    1. Pybus BS, Sousa JC, Jin X, Ferguson JA, Christian RE, Barnhart R, Vuong C, Sciotti RJ, Reichard GA, Kozar MP, Walker LA, Ohrt C, Melendez V. 2012. CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine. Malar. J. 11:259. 10.1186/1475-2875-11-259.
    1. Ganesan S, Tekwani BL, Sahu R, Tripathi LM, Walker LA. 2009. Cytochrome P450-dependent toxic effects of primaquine on human erythrocytes. Toxicol. Appl. Pharmacol. 241:14–22. 10.1016/j.taap.2009.07.012.
    1. European Medicines Agency. 2012. Eurartesim: EPAR–product information. European Medicines Agency, London, United Kingdom: .
    1. Tarning J, Rijken MJ, McGready R, Phyo AP, Hanpithakpong W, Day NP, White NJ, Nosten F, Lindegardh N. 2012. Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria. Antimicrob. Agents Chemother. 56:1997–2007. 10.1128/AAC.05756-11.
    1. Ilett KF, Ethell BT, Maggs JL, Davis TM, Batty KT, Burchell B, Binh TQ, Thu le TA, Hung NC, Pirmohamed M, Park BK, Edwards G. 2002. Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. Drug Metab. Dispos. 30:1005–1012. 10.1124/dmd.30.9.1005.
    1. Nguyen DV, Nguyen QP, Nguyen ND, Le TT, Nguyen TD, Dinh DN, Nguyen TX, Bui D, Chavchich M, Edstein MD. 2009. Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam. Antimicrob. Agents Chemother. 53:3534–3537. 10.1128/AAC.01717-08.
    1. Baird JK, Fryauff DJ, Hoffman SL. 2003. Primaquine for prevention of malaria in travelers. Clin. Infect. Dis. 37:1659–1667. 10.1086/379714.
    1. Karunajeewa H, Lim C, Hung TY, Ilett KF, Denis MB, Socheat D, Davis TM. 2004. Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria. Br. J. Clin. Pharmacol. 57:93–99. 10.1046/j.1365-2125.2003.01962.x.
    1. Mytton OT, Ashley EA, Peto L, Price RN, La Y, Hae R, Singhasivanon P, White NJ, Nosten F. 2007. Electrocardiographic safety evaluation of dihydroartemisinin piperaquine in the treatment of uncomplicated falciparum malaria. Am. J. Trop. Med. Hyg. 77:447–450.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel